In a recent disclosure, Farallon Capital Management reported establishing a significant new stake in Natera, Inc. (NTRA), a leader in cell-free DNA (cfDNA) testing. The investment firm acquired 3.21 million shares valued at approximately $641.44 million, giving it a 3.66% weight in its reported portfolio. Natera specializes in genetic testing for women's health, oncology, and organ health.
Investors should note that 13F filings reflect positions held at the end of a prior quarter and are not indicative of current trading activity. This particular filing, dated August 14, 2026, details Farallon's holdings as of March 31, 2026. Therefore, the sizable investment in the genetic diagnostics company was made at some point during the first quarter of the year.